US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alcobra

10.22

0.0000

Volume:- -

Turnover:- -

Market Cap:281.69M

PE:-11.48

High:10.22

Open:10.22

Low:10.22

Close:10.22

Loading ...

Overview Company News Filings

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals

Supernus to Participate in Two Upcoming Investor Conferences

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025

This child psychiatrist dedicated her life to autism and mental health research because of her special needs son

Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

ACCESS Newswire

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

ACCESS Newswire

Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

MT Newswires Live

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

People with ADHD are more likely to die early, according to a new study

businessinsider.com

ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market

AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees

Final Study Completed for Cingulate’s Lead Asset CTx-1301

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ADHD/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADHD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","market":"US","secType":"STK","nameCN":"Alcobra","latestPrice":10.22,"timestamp":1510952400000,"preClose":10.22,"halted":4,"volume":0,"delay":0,"floatShares":8881019,"shares":27563000,"eps":-0.89,"marketStatus":"Delisted","change":0,"latestTime":"11-17 16:00:00 EST","open":10.22,"high":10.22,"low":10.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","floatShares":8881019,"roa":"--","roe":"--","lyrEps":0,"shares":27563000,"dividePrice":0,"high":10.22,"amplitude":0,"preClose":10.22,"low":10.22,"week52Low":5.8113,"pbRate":"5.96","week52High":18.0414,"institutionHeld":0,"latestPrice":10.22,"eps":-0.89,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.89,"open":10.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADHD\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518782331","title":"Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2518782331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518782331?lang=en_us&edition=fundamental","pubTime":"2025-03-11 06:57","pubTimestamp":1741647420,"startTime":"0","endTime":"0","summary":"STOUGHTON, Mass., March  10, 2025  (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3040237/34897/en/Collegium-Announces-Poster-Presentations-at-the-2025-National-Association-of-Pediatric-Nurse-Practitioners-National-Conference-on-Pediatric-Health-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","HCP","NHLD","BK4588","BK4585","ABVC","BK4139","ADHD","BK4194","CNS","DEA","BK4223","BK4023","CII"],"gpt_icon":0},{"id":"2517191949","title":"AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2517191949","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517191949?lang=en_us&edition=fundamental","pubTime":"2025-03-06 23:27","pubTimestamp":1741274820,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi .The settlement agreement resolves the patent litigation brought by Axsome on Hikma for submitting an abbreviated new drug application to the FDA, seeking marketing approval for a generic version of Sunosi in the United States. The patent litigation is pending in the United States District Court for the District of New Jersey.Axsome acquired U.S. rights to Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. It began selling Sunosi in the U.S. market in May 2022 and in certain international markets in November 2022.Jazz had received approval for Sunosi as a treatment for narcolepsy in 2019.JAZZ is entitled to receive a high single-digit royalty from Axsome on net sales of Sunosi in the United States. AXSM out-licensed its ex-U.S. marketing rights of Sunosi to Pharmanovia in February 2023.In the past year, shares of Axsome have ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsm-settles-sunosi-patent-litigation-152700923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BN0W2W23.USD","ADHD","LU0889565916.HKD","RIGL","LU0320765992.SGD","ABVC","BK4532","IE00BN0W2T93.GBP","LU0109394709.USD","AXSM","JAZZ","ANIP","BK4007","LU0823416689.USD","BK4585","IE00BN0W2V16.EUR","BK4533","BK4505","BK4139"],"gpt_icon":0},{"id":"2517981626","title":"Supernus to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2517981626","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517981626?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:30","pubTimestamp":1741123800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., March  04, 2025  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036999/19871/en/Supernus-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","BK4135","LU1169589451.USD","BK4023","CNS","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2516674892","title":"Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674892","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674892?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:00","pubTimestamp":1741096800,"startTime":"0","endTime":"0","summary":"Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2 CTx-1301 is the First, True, Once-Daily Stimulant Medication to Treat ADHD Over the Entire Active Day KANSAS CITY, Kan.,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/04/3036578/0/en/Cingulate-Reports-Safety-Results-from-Final-Phase-3-Trials-for-Lead-ADHD-Asset-CTx-1301-On-Track-to-File-for-FDA-Approval-Mid-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","API","BK4551","BK4503","BK4139","BK4007","BK4023","ABVC","ADHD","BK4535"],"gpt_icon":0},{"id":"2512112756","title":"This child psychiatrist dedicated her life to autism and mental health research because of her special needs son","url":"https://stock-news.laohu8.com/highlight/detail?id=2512112756","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512112756?lang=en_us&edition=fundamental","pubTime":"2025-02-19 07:12","pubTimestamp":1739920320,"startTime":"0","endTime":"0","summary":"Dr Sung Min channelled her experience as a mother to a child with autism spectrum disorder to her research. She established autism services at the Institute of Mental Health and her team is now focused on the mental health of young people with autism.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--iRTiLJ6X--/c_crop,h_410,w_546,x_0,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/02/12/institute_of_mental_health_child_psychiatrist_dr_sung_min_with_her_son.jpg?itok=j8YxPMqc","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--iRTiLJ6X--/c_crop,h_410,w_546,x_0,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/02/12/institute_of_mental_health_child_psychiatrist_dr_sung_min_with_her_son.jpg?itok=j8YxPMqc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/women/child-psychiatrist-dr-sung-min-autism-research-institute-mental-health-4932941","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4229","CBT","BK4090","IMH","BK4195","ADHD"],"gpt_icon":0},{"id":"2512974441","title":"Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2512974441","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512974441?lang=en_us&edition=fundamental","pubTime":"2025-02-19 05:25","pubTimestamp":1739913900,"startTime":"0","endTime":"0","summary":"Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3028344/19871/en/Supernus-Announces-Topline-Results-from-Phase-2b-Study-in-Adults-with-Treatment-Resistant-Depression.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","BK4135","CNS","LU1169589451.USD","LU1169590202.USD","PD","ADHD"],"gpt_icon":0},{"id":"2512156706","title":"Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2512156706","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512156706?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth. Auvelity 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively, representing 89% and 124% year-over-year growth. Symbravo approved in the U.S. for the acute treatment of migraine with or without aura in adults. Total net product revenues were $118.8 million and $385.7 million for the fourth quarter and full year of 2024, representing 66% and 88% year-over-year growth, respectively. Total net product revenues for the comparable periods in 2023 were $71.5 million and $204.9 million, respectively.Auvelity net product sales were $92.6 million and $291.4 million for the fourth quarter and full year of 2024, representing 89% and 124% year-over-year growth, respectively. Auvelity net product sales for the comparable periods in 2023 were $49.0 million and $130.1 million, respectively.Sunosi net product revenues w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-therapeutics-reports-fourth-quarter-120000921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4007","ADHD","CNS","AXSM","BK4505","BK4135","BK4585","BK4139"],"gpt_icon":0},{"id":"2511586749","title":"This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2511586749","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511586749?lang=en_us&edition=fundamental","pubTime":"2025-02-16 21:45","pubTimestamp":1739713500,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics settled a patent litigation lawsuit that posed a significant risk to its prospects.The biotech also has a strengthening lineup and several exciting late-stage pipeline programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/16/this-stock-is-already-up-51-in-2025-is-it-too-late/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["ADHD","ABVC","BK4139"],"gpt_icon":0},{"id":"2511580225","title":"Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580225","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580225?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:03","pubTimestamp":1739394180,"startTime":"0","endTime":"0","summary":"First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023. Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time. DENVER, CO / ACCESS Newswire / February 12, 2025 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.Pediatric Portfolio  net revenue increased 86% sequentially to $2.4 million versus $1.3 million in Q1 fiscal 2025, reflecting positive effects from recently implemented return-to-growth plan for the pediatric product line. Pediatric Portfolio net revenue increased 12% compared to Q2 fiscal 2024.ADHD Portfolio  net revenue increased 16% sequentially to $13.8 million versus $11.9 million in Q1 fiscal 2025 after adjusting for a one-time vendor agreement positively impacting Q1 fiscal 2025 net revenue by $3.3 million.\"This positive commercial momentum paralle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-reports-fiscal-2025-210300699.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADHD","AYTU","ABVC","BK4139","BK4007"],"gpt_icon":0},{"id":"2510350910","title":"Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510350910","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510350910?lang=en_us&edition=fundamental","pubTime":"2025-02-12 05:30","pubTimestamp":1739309400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Feb.  11, 2025  (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/11/3024625/19871/en/Supernus-Pharmaceuticals-to-Host-Conference-Call-and-Webcast-on-February-25-2025-to-Discuss-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","HST","BK4585","BK4135","CNS","ADHD","BK4181","BK4007","BK4588","BK4218","LU1169590202.USD","SUPN","LU1169589451.USD"],"gpt_icon":0},{"id":"2510855076","title":"RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties","url":"https://stock-news.laohu8.com/highlight/detail?id=2510855076","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510855076?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"Glen Rock, N.J., Feb. 10, 2025  -- RespireRx Pharmaceuticals Inc. , a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties.Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties:. One of the things we started in 2023 and continued in January 2025 is the establishment of subsidiaries that we believe will provide substantial benefits to the Company going forward. In 2023, we established ResolutionRx Ltd as a wholly-owned Australian subsidiary to further the development of our cannabinoid program, particularly dronabinol, with a new proprietary formulation, initially for the treatment of obstructive sleep apnea. In January 2025 we converted our business unit, EndeavourRx into a wholly-owned subsidiary, EndeavourRx LL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/respirerx-pharmaceuticals-inc-cfo-ceo-120000978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","GABA","ADHD","BK4211","RSPI","BDC","BK4148"],"gpt_icon":0},{"id":"2509263540","title":"Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509263540","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509263540?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:50","pubTimestamp":1738795800,"startTime":"0","endTime":"0","summary":"DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, will report its operational and financial results for its second quarter of fiscal 2025, after the market close on Wednesday, February 12, 2025. The Company has scheduled a conference call and webcast that same day, Wednesday, February 12, 2025, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.Call-in Information: Interested parties can access the conference call by dialing  506-0062 for United States callers or +1  528-0011 for international callers and using the participant access code 583044.Replay: A teleconference replay of the call will be available until February 26, 2025 at  481-4010 for U.S. callers or +1  882-2331 for international callers and using replay access code 51953.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-report-fiscal-2025-225000048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADHD","BK4007","AYTU"],"gpt_icon":0},{"id":"2508454681","title":"Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2508454681","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508454681?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:00","pubTimestamp":1738677600,"startTime":"0","endTime":"0","summary":"ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s diseaseONAPGO is a wearable subcutaneous infusion devi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/04/3020423/19871/en/Supernus-Announces-FDA-Approval-of-ONAPGO-apomorphine-hydrochloride-for-Parkinson-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","CNS","BK4135","ADHD","PD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2506308527","title":"Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree","url":"https://stock-news.laohu8.com/highlight/detail?id=2506308527","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506308527?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:35","pubTimestamp":1737988518,"startTime":"0","endTime":"0","summary":"Supernus Pharmaceuticals (SUPN) said Monday the US Food and Drug Administration has cleared a label update for qelbree, a treatment for attention-deficit/hyperactivity disorder, or ADHD.The updated la","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABVC","SUPN","ADHD","BK4007","BK4139"],"gpt_icon":0},{"id":"2506743963","title":"Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women","url":"https://stock-news.laohu8.com/highlight/detail?id=2506743963","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506743963?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:00","pubTimestamp":1737982800,"startTime":"0","endTime":"0","summary":"Updated label includes new data in Section 12.2, detailing serotonin 5-HT2C partial agonist activity and norepinephrine transporter inhibition, highlighting Qelbree’s multimodal pharmacodynamics. Qelbree is the first ADHD treatment to meet its post marketing requirement and receive labeling approval following the 2019 FDA guidance on Clinical Lactation Studies1. The update to include lactation data in the label  follows the 2019 FDA guidance suggesting lactation studies be conducted to inform breastfeeding with drug use recommendations and is based on a study involving 15 healthy lactating women.The study evaluated the secretion of viloxazine and its metabolite  into breast milk following a multi-dose  regimen of viloxazine. Results showed that the estimated daily infant dose  of viloxazine and 5-HVLX-gluc was 0.085 mg/kg and 0.00595 mg/kg, respectively, and the relative infant dose was approximately 1% and 0.07%, respectively, of the weight-normalized maternal daily dose  of viloxazin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/supernus-announces-label-non-stimulant-130000268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PD","SUPN","LU1169589451.USD","CNS","ADHD","ABVC","BK4134","III","BK4007","BK4023","LU1169590202.USD","BK4139","BK4135"],"gpt_icon":0},{"id":"2505404685","title":"People with ADHD are more likely to die early, according to a new study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505404685","media":"businessinsider.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505404685?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:03","pubTimestamp":1737648189,"startTime":"0","endTime":"0","summary":"A new study found that people with ADHD likely have a shorter life expectancy.Men died about seven years earlier and women died nine years sooner than their peers.ADHD is linked to more impulsive or d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businessinsider.com/people-with-adhd-likely-to-die-earlier-new-study-2025-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"businsider_highlight","symbols":["ADHD","BK4139","ABVC"],"gpt_icon":0},{"id":"2503641133","title":"ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2503641133","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503641133?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:30","pubTimestamp":1736947800,"startTime":"0","endTime":"0","summary":"Polygala tenuifolia, or Yuan Zhi, has long been utilized in traditional Chinese medicine to improve cognitive function and mental clarity. Its root contains bioactive compounds like polygala saponins and xanthones, which exhibit neuroprotective and anxiolytic properties. Studies reveal that these compounds modulate the dopaminergic and serotonergic pathways, offering therapeutic potential for mood disorders and ADHD.[2] Additionally, its antioxidant properties enhance neuroplasticity, making it a promising candidate for holistic mental health care.[3]. ABVC BioPharma has harnessed the therapeutic potential of Polygala tenuifolia in its proprietary PDC-1421 formulation. Recent internal clinical trials underscore the efficacy and safety of PDC-1421 in treating ADHD and MDD, addressing our perceived growing demand for natural, plant-based alternatives to synthetic drugs.MDD Treatment :PDC-1421 achieved a MontgomeryAsberg Depression Rating Scale  score reduction of -13.21 from baseline ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-adhd-mdd-drug-133000095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ITT","R","BK4022","ABVC","PP","BK4161","LU0054578231.USD","ADHD","LU0053671581.USD","BK4139","BK4232"],"gpt_icon":0},{"id":"2503755576","title":"AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees","url":"https://stock-news.laohu8.com/highlight/detail?id=2503755576","media":"NewMediaWire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503755576?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861400,"startTime":"0","endTime":"0","summary":"Licensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl's Plans. These incremental licensing fees highlight AiBtl's commitment to ABVC's innovative biopharma pipeline and reinforce this partnership's strategic benefits. AiBtl is focused on developing cutting-edge natural therapies that it believes can create long-term value for its investors and stakeholders.\"This milestone represents another step in AiBtl's growth journey,\" said Russ Jaimes, CEO of AiBtl BioPharma. \"With the continued support of ABVC and our strategic partners, we are well-positioned to execute our growth plans and expand our market presence.\". ABVC BioPharma is strategically positioned in growing markets. The global MDD market is projected to grow from $11.51 billion in 2022 to $14.96 billion by 2032, with a steady CAGR of 2.8%.[1] The global ADHD treatment market is also growing, expected to increase from $15.23 billion in 2022 at a CAGR of 7.3% through 2032.[2] Additional","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aibtl-biopharma-strengthens-partnership-abvc-133000542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["R","BK4022","ABVC","BK4232","BK4139","ADHD"],"gpt_icon":0},{"id":"2501203113","title":"Final Study Completed for Cingulate’s Lead Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2501203113","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501203113?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:30","pubTimestamp":1736253000,"startTime":"0","endTime":"0","summary":"No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025. KANSAS CITY, Kan., Jan. 07, 2025  -- Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release  drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has completed its final FDA-required study, which is a food effect study, for CTx-1301  for the treatment of Attention Deficit Hyperactivity Disorder .The primary PK endpoints were maximum concentration  during the first 28 hours after dosing, and the total amount of the active pharmaceutical ingredient , dexmethylphenidate, in the blood  from dosing to the time of the last measured concentration  and from dosing taken to the limit as the end time becomes arbitrarily large . Overall, the effect of food on the PK of orally administered long-acting stimulants is generally minimal: following a high-fat meal, there is potential for the ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/final-study-completed-cingulate-lead-123000121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4535","PK","BK4139","CINGW","BK4551","API","BK4181","BK4503","BK4007","CING","ABVC","ADHD","BK4023","ADME"],"gpt_icon":0},{"id":"2501308122","title":"Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501308122","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501308122?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:00","pubTimestamp":1736172000,"startTime":"0","endTime":"0","summary":"DENVER, CO / ACCESSWIRE / January 6, 2025 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced that CEO, Josh Disbrow, will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.Mr. Disbrow will discuss the Company's plans for 2025. Topics are expected to include the impact of Aytu's successful, multi-year, strategic realignment to focus on its profitable prescription pharmaceutical business and leveraging Aytu's unique capabilities of the now streamlined organization. These changes should allow for growing the Company's novel, commercialized prescription therapeutics, while also driving cash flow and profitability. Further, Mr. Disbrow is expected to discuss how RxConnect, Aytu's proprietary, best-in-class patient access program, enables affordable, predictable, hassle-free patient access to Aytu Rx products and enables integration ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-participate-lytham-partners-140000167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCSG","BK4211","AYTU","BK4007","SMMF","BK4137","ADHD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADHD\",params:#limit:5,,,undefined,":[{"date":"2017-11-16","symbol":"ADHD","newSymbol":"ARCT","type":"symbolChange","dateTimestamp":1510808400000},{"date":"2017-11-15","symbol":"ADHD","type":"split","dateTimestamp":1510722000000,"forFactor":7,"toFactor":1},{"market":"US","date":"2017-11-09","symbol":"ADHD","fiscalQuarterEnding":"2017/09","expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2017-08-11","symbol":"ADHD","fiscalQuarterEnding":"2017/06","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1502424000000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2017-05-30","symbol":"ADHD","fiscalQuarterEnding":"2017/03","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1496116800000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADHD\",market:\"US\",delay:false,,,undefined,":{}}}